药明康德(603259) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was RMB 10.46 billion, a decrease of 1.96% year-over-year[5] - Net profit attributable to shareholders for the third quarter was RMB 2.29 billion, down 17.02% year-over-year[5] - Cumulative revenue for the first three quarters of 2024 was RMB 27.70 billion, a decrease of 6.23% year-over-year[5] - Cumulative net profit attributable to shareholders for the first three quarters was RMB 6.53 billion, down 19.11% year-over-year[5] - Basic earnings per share for the third quarter were RMB 0.80, a decrease of 14.89% year-over-year[5] - Weighted average return on equity (ROE) for the third quarter was 4.12%, down 1.47 percentage points year-over-year[6] - Total revenue for the first three quarters of 2024 reached RMB 277.0 billion, a 4.6% increase excluding specific commercial production projects[10] - Total revenue for the first three quarters of 2024 was RMB 27,702,002,254.76, a decrease of 6.2% compared to RMB 29,541,326,133.58 in the same period of 2023[24] - Net profit for the first three quarters of 2024 was RMB 6,601,611,515.97, a decrease of 19.0% compared to RMB 8,148,647,084.33 in the same period of 2023[24] - Operating profit for the first three quarters of 2024 was RMB 7,890,869,263.36, a decrease of 19.5% compared to RMB 9,807,416,477.55 in the same period of 2023[24] - Comprehensive income for the first three quarters of 2024 reached 6,598,257,681.21 yuan, a decrease from 7,604,711,326.21 yuan in the same period of 2023[25] - Basic earnings per share for the first three quarters of 2024 were 2.25 yuan, down from 2.75 yuan in the same period of 2023[25] - Revenue for the first three quarters of 2024 was 27,702,002 thousand yuan, a decrease from 29,541,326 thousand yuan in the same period of 2023[30] - Gross profit for the first three quarters of 2024 was 11,098,161 thousand yuan, down from 12,071,476 thousand yuan in the same period of 2023[30] - Operating profit for the first three quarters of 2024 was 7,842,527 thousand yuan, compared to 9,988,476 thousand yuan in the same period of 2023[30] - Net profit for the first three quarters of 2024 was 6,601,612 thousand yuan, a decrease from 8,148,647 thousand yuan in the same period of 2023[30] - Net profit attributable to parent company holders in Q3 2024 was RMB 2,293,113 thousand, a decrease from RMB 2,763,287 thousand in Q3 2023[32] - Total comprehensive income for the first nine months of 2024 was RMB 6,598,258 thousand, down from RMB 7,604,712 thousand in the same period of 2023[32] - Adjusted non-IFRS net profit attributable to parent company owners for Q3 2024 was RMB 2,973.5 million, compared to RMB 3,072.4 million in Q3 2023, a decrease of 3.2%[37] - Adjusted non-IFRS net profit attributable to parent company owners for the first three quarters of 2024 was RMB 7,345.7 million, compared to RMB 8,167.1 million in the same period of 2023, a decrease of 10.1%[37] - Net profit attributable to parent company owners for Q3 2024 was RMB 2,293.1 million, a decrease of 17.0% compared to RMB 2,763.3 million in Q3 2023[37] - Net profit attributable to parent company owners for the first three quarters of 2024 was RMB 6,532.9 million, a decrease of 19.1% compared to RMB 8,076.4 million in the same period of 2023[37] Business Segment Performance - Revenue from the chemical business (WuXi Chemistry) for the first three quarters was RMB 20.09 billion, down 5.40% year-over-year[8] - Revenue from the testing business (WuXi Testing) for the first three quarters was RMB 4.62 billion, down 4.86% year-over-year[8] - WuXi Biology revenue decreased by 3.64% to RMB 182,594.01 million in Q3 2024[9] - WuXi ATU revenue declined by 17.04% to RMB 85,303.65 million in Q3 2024[9] - WuXi DDSU revenue dropped by 41.01% to RMB 28,970.17 million in Q3 2024[9] - Revenue from global top 20 pharmaceutical companies reached RMB 11.22 billion, up 23.1% excluding specific commercial production projects[10] - TIDES business revenue surged 71.0% to RMB 3.55 billion in the first three quarters of 2024[11] - Small molecule D&M business revenue grew 7.0% to RMB 12.47 billion excluding specific commercial production projects[11] - Clinical CRO and SMO business revenue increased by 3.4% to RMB 1.36 billion in the first three quarters of 2024[13] - Biology business revenue reached RMB 1.83 billion, with new molecule-related business growing 6.0%[13] - CTDMO business revenue was RMB 850 million, impacted by project delays and new order shortages[14] Financial Position - Total assets as of the end of the third quarter were RMB 74.24 billion, an increase of 0.77% compared to the end of the previous year[6] - Total assets as of September 30, 2024, were RMB 74,238,239,875.23, an increase of 0.8% compared to RMB 73,669,349,307.12 at the end of 2023[21] - Total liabilities as of September 30, 2024, were RMB 18,654,997,773.24, an increase of 2.8% compared to RMB 18,151,903,894.38 at the end of 2023[22] - Cash and cash equivalents as of September 30, 2024, were RMB 14,051,541,214.47, an increase of 2.1% compared to RMB 13,764,058,665.13 at the end of 2023[21] - Accounts receivable as of September 30, 2024, were RMB 8,014,543,781.69, an increase of 1.4% compared to RMB 7,901,380,298.53 at the end of 2023[21] - Inventory as of September 30, 2024, was RMB 5,347,792,758.02, an increase of 12.9% compared to RMB 4,736,229,956.28 at the end of 2023[21] - Total equity attributable to owners of the parent company as of September 30, 2024, was RMB 55,173,547,660.38, an increase of 0.1% compared to RMB 55,122,453,910.73 at the end of 2023[22] - Property, plant, and equipment increased to RMB 26,006,848 thousand as of September 30, 2024, compared to RMB 25,844,429 thousand at the end of 2023[33] - Total assets as of September 30, 2024, were RMB 74,238,240 thousand, up from RMB 73,669,349 thousand at the end of 2023[33] - Total liabilities as of September 30, 2024, were RMB 18,654,998 thousand, up from RMB 18,151,904 thousand at the end of 2023[34] - Cash and cash equivalents at the end of September 2024 were RMB 9,271,603 thousand, down from RMB 10,001,039 thousand at the end of 2023[33] Cash Flow - Net cash flow from operating activities for the first three quarters of 2024 was 8,379,092,385.15 yuan, compared to 10,316,787,859.57 yuan in the same period of 2023[27] - Net cash flow from investing activities for the first three quarters of 2024 was -3,194,216,873.13 yuan, an improvement from -5,781,965,276.30 yuan in the same period of 2023[27] - Net cash flow from financing activities for the first three quarters of 2024 was -5,904,884,477.90 yuan, compared to -3,303,987,419.68 yuan in the same period of 2023[29] - Net cash generated from operating activities for the first nine months of 2024 was RMB 8,052,215 thousand, a decrease from RMB 9,847,742 thousand in the same period of 2023[35] - Net cash used in investing activities for the first nine months of 2024 was RMB 2,866,621 thousand, compared to RMB 5,316,765 thousand in the same period of 2023[35] - Net cash used in financing activities for the first nine months of 2024 was RMB 5,905,603 thousand, an increase from RMB 3,300,141 thousand in the same period of 2023[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 385,041[17] - HKSCC NOMINEES LIMITED holds 387,025,502 shares, representing 13.2910% of the total shares[17] - Hong Kong Securities Clearing Company Limited holds 143,295,973 shares, representing 4.9210% of the total shares[17] - G&C VI Limited holds 143,015,795 shares, representing 4.9114% of the total shares[17] - G&C IV Hong Kong Limited holds 104,626,051 shares, representing 3.5930% of the total shares[17] - Beijing Zhongmin Yinfu Investment Management Co., Ltd. holds 87,074,568 shares, representing 2.9903% of the total shares[17] - G&C V Limited holds 73,105,843 shares, representing 2.5106% of the total shares[17] - China Industrial and Commercial Bank Co., Ltd. holds 63,865,186 shares, representing 2.1932% of the total shares[17] - SUMMER BLOOM INVESTMENTS (I) PTE. LTD. holds 60,597,907 shares, representing 2.0810% of the total shares[17] - China Bank Co., Ltd. holds 57,123,648 shares, representing 1.9617% of the total shares[17] Expenses and Other Financial Metrics - Research and development expenses for the first three quarters of 2024 were RMB 954,042,826.94, a decrease of 7.0% compared to RMB 1,025,811,070.87 in the same period of 2023[24] - Equity incentive expenses for Q3 2024 were RMB 79.4 million, a decrease of 49.2% compared to RMB 156.2 million in Q3 2023[37] - Equity incentive expenses for the first three quarters of 2024 were RMB 244.4 million, a decrease of 49.1% compared to RMB 480.6 million in the same period of 2023[37] - Exchange rate fluctuation-related losses for Q3 2024 were RMB 629.8 million, compared to a gain of RMB 18.3 million in Q3 2023[37] - Exchange rate fluctuation-related losses for the first three quarters of 2024 were RMB 658.7 million, compared to a gain of RMB 354.8 million in the same period of 2023[37] - Amortization of intangible assets from acquisitions for Q3 2024 was RMB 13.3 million, a decrease of 10.1% compared to RMB 14.8 million in Q3 2023[37] - Amortization of intangible assets from acquisitions for the first three quarters of 2024 was RMB 40.3 million, a decrease of 6.9% compared to RMB 43.3 million in the same period of 2023[37]